Moreover, with accumulating data on non-melanoma BRAF-driven cancers, it is expected that the number of clinical trials testing co-targeting of autophagy plus RAF > MEK > ERK signaling will expand in the near future. This evidence concerns the gene MAP2K7 and melanoma.